双膦酸盐预处理对特立帕肽骨密度增益及骨折结局的影响:系统评价与荟萃分析
结果显示预处理与腰椎骨密度增益小幅降低相关,髋部及股骨颈无显著差异;骨折绝对事件合并提示风险较高,但校正后风险比无统计学显著性。
要点
- 双膦酸盐预处理者特立帕肽治疗后腰椎骨密度增益较未预处理者平均低2.21%。
- 髋部和股骨颈骨密度变化在两组间无显著差异。
- 骨折数据结论不一致,校正分析未显示明确保护减弱。
核心结论
- 双膦酸盐预处理与特立帕肽治疗后腰椎骨密度增益小幅衰减相关,非脊柱部位无显著影响。
- 现有骨折数据尚不确定,校正分析未明确显示骨折保护作用减弱。
- 临床指征明确时,支持在双膦酸盐之前或之后继续使用特立帕肽。
研究设计与样本
- 遵循PRISMA指南的系统评价与荟萃分析(PROSPERO: CRD420251234859)。
- 纳入随机试验、非随机试验、观察性研究及事后或亚组分析,比较双膦酸盐预处理与未预处理者的特立帕肽疗效。
- 采用随机效应模型及Hartung-Knapp校正。
主要发现
- 双膦酸盐预处理与腰椎骨密度增益显著较小相关(平均差-2.21%;95%CI -4.17,-0.25;p=0.027)。
- 髋部骨密度变化无显著差异(平均差-0.88%;95%CI -1.98,0.19;p=0.108)。
- 股骨颈骨密度变化无显著差异(平均差-0.52%;95%CI -1.36,0.33;p=0.230)。
- 合并绝对骨折事件提示预处理者骨折风险较高(OR 1.43;95%CI 1.09,1.88;p=0.009)。
- 合并校正风险比未显示统计学显著差异(HR 1.35;95%CI 0.99,1.83;p=0.055)。
关键数值与推荐
- 腰椎骨密度增益平均差-2.21%(95%CI -4.17,-0.25;p=0.027),提示预处理者增益较小。
- 髋部骨密度平均差-0.88%(95%CI -1.98,0.19;p=0.108),无显著差异。
- 股骨颈骨密度平均差-0.52%(95%CI -1.36,0.33;p=0.230),无显著差异。
- 骨折绝对事件OR 1.43(95%CI 1.09,1.88;p=0.009)。
- 校正骨折风险HR 1.35(95%CI 0.99,1.83;p=0.055),无统计学显著性。
临床怎么用
- 临床指征明确时,可在双膦酸盐治疗前或治疗后使用特立帕肽。
- 对双膦酸盐预处理患者,应关注腰椎骨密度增益可能小幅降低。
- 骨折保护作用是否受预处理影响尚不明确,需结合个体情况综合判断。
局限性
- 骨折数据结论不一致,校正分析仅基于两项研究。
- 双膦酸盐预处理对特立帕肽应答的临床相关性尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Teriparatide is a potent anabolic therapy for osteoporosis and is frequently prescribed after prior bisphosphonate (BP) treatment in routine clinical practice. Whether such pretreatment alters teriparatide efficacy, particularly with respect to fracture outcomes, remains uncertain. METHODS: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines (PROSPERO: CRD420251234859). PubMed/MEDLINE, Embase, and Scopus were searched from inception to November 30, 2025. Randomized trials, non-randomized trials, observational studies, and post hoc or subgroup analyses comparing teriparatide efficacy in BP-pretreated versus BP-naïve individuals were included. Outcomes included percentage change in areal bone mineral density (BMD) at the lumbar spine, hip, and femoral neck, and incident fractures. Random-effects models with Hartung-Knapp adjustment were used. RESULTS: Fifteen studies involving 8,763 BP-pretreated and 7,071 BP-naïve individuals were analysed. Prior BP exposure was associated with a significantly smaller increase in lumbar spine BMD following teriparatide (mean difference [MD] -2.21%; 95% CI -4.17,-0.25; p = 0.027). No significant differences were observed at the hip (MD -0.88%; 95% CI -1.98,0.19; p = 0.108) or femoral neck (MD -0.52%; 95% CI -1.36,0.33; p = 0.230). Pooling of absolute fracture events suggested a higher fracture risk in BP-pretreated patients (OR 1.43; 95% CI 1.09,1.88; p = 0.009), whereas pooled adjusted hazard ratios did not show a statistically significant difference (HR 1.35; 95% CI 0.99,1.83; p = 0.055). CONCLUSIONS: Prior bisphosphonate exposure is associated with modest, site-specific attenuation of lumbar spine BMD gains with teriparatide, without significant effects at non-spinal sites. Available fracture data remain inconclusive and adjusted analyses, albeit based on only two studies, do not indicate a clear attenuation of fracture protection. Prior bisphosphonate exposure may attenuate teriparatide response, but its clinical relevance is unclear. In this meta-analysis, lumbar spine BMD gains were modestly reduced, while hip/femoral neck BMD and adjusted fracture outcomes were not significantly affected. These findings support the continued use of teriparatide either before or after bisphosphonates when clinically indicated.
引用
- Pal R, Banerjee M, Yadav U, et al. Influence of bisphosphonate pretreatment on bone mineral density gains and fracture outcomes with teriparatide: A systematic review and meta-analysis. Osteoporos Int. 2026. PMID: 42455318. doi:10.1007/s00198-026-08136-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。